It’s a phase 2b double blind randomised placebo-controlled clinical trial.
The answer is “couldn’t”.
The patent application includes the unblinded data. What does that tell you?
Some of you guys are addicted to the share price because you don’t understand the fundamentals. Is that condescending, yes and for good reason. Don’t forget there was a big seller at 8c who sold a lot of stock to @Chaya and here we are at 24.5c. Why? Because he did his research and didn’t get frightened by the market noise.
DYOR or turn your computer off. If IHL was a private company you’d be ecstatic with the recent news. And yes, if you want me to take a break from posting because you’re offended it will be my pleasure.
- Forums
- ASX - By Stock
- IHL
- Ann: IHL-42X patent update & open label extension study approval
Ann: IHL-42X patent update & open label extension study approval, page-181
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)